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Duplications and deletions are known to cause a number of genetic disorders, yet technical difficulties and financial
considerations mean that screening for these mutations, especially duplications, is often not performed. We have
adapted multiplex amplifiable probe hybridization (MAPH) for the screening of the DMD gene, mutations in which
cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. MAPH involves the quantitative
recovery of specifically designed probes following hybridization to immobilized genomic DNA. We have engineered
probes for each of the 79 exons of the DMD gene, and we analyzed them by using a 96-capillary sequencer. We
screened 24 control individuals, 102 patients, and 23 potential carriers and detected a large number of novel
rearrangements, especially small, one- and two-exon duplications. A duplication of exon 2 alone was the most
frequently occurring mutation identified. Our analysis indicates that duplications occur in 6% of patients with
DMD. The MAPH technique as modified here is simple, quick, and accurate; furthermore, it is based on existing
technology (i.e., hybridization, PCR, and electrophoresis) and should not require new equipment. Together, these
features should allow easy implementation in routine diagnostic laboratories. Furthermore, the methodology should
be applicable to any genetic disease, it should be easily expandable to cover 1200 probes, and its characteristics
should facilitate high-throughput screening.
Introduction
Most techniques currently applied to reveal disease-caus-
ing mutations are PCR based and do not readily produce
quantitative data. Consequently, although copy-number
changes (i.e., deletions and duplications) are frequently
involved, they will go undetected unless specific tech-
niques are applied (Petrij-Bosch et al. 1997; Wijnen et
al. 1998; Morgan et al. 1999). The major reason behind
this failure is economical: obtaining quantitative data is
feasible but is technically demanding, labor intensive,
and, thus, costly. When specific precautions are taken,
Southern blotting and quantitative PCR are able to de-
tect deletions and/or duplications, but they are both la-
borious and difficult to implement on a routine basis.
A technique that might fill this gap has recently been
described—namely, multiplex amplifiable probe hybrid-
ization (MAPH) (fig. 1) (Armour et al. 2000). MAPH is
based on the quantitative recovery of probes, after their
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hybridization to immobilized DNA. Each probe is en-
gineered to allow simultaneous amplification with only
one set of primers. This overcomes one of the most dif-
ficult elements of quantitative multiplex PCR—namely,
differences, between primers, in annealing efficiency. In
the originalMAPH protocol, after the hybridization step,
the PCR products were radioactively labeled during PCR
amplification andwere analyzed on a polyacrylamide gel.
To facilitate a more-automated, higher-throughput ap-
plication ofMAPH, we have chosen to label the products
fluorescently and to separate them on a 96-capillary se-
quencer. Each product is identifiable on the basis of
length, with the size of the resultant peak being directly
proportional to the copy number of the relevant probe.
Changes in peak heights will therefore reflect deletions
and duplications in genomic DNA.
We have applied the modified MAPH protocol to scan
for copy-number changes in patients with Duchenne
muscular dystrophy (DMD) (MIM #310200). DMD is
the most commonly inherited neuromuscular disease, af-
fecting 1 in 3,500 male individuals (Worton and Thomp-
son 1988). It is an X-linked disorder that is caused by
mutations in the DMD gene. This gene is the largest
known, covering 2.4 Mb (den Dunnen et al. 1989; Boyce
et al. 1991) and containing 79 exons that encode a 14-
kb mRNA (Koenig et al. 1987). Translation-truncating
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Figure 1 Outline of the MAPH technique. Probes are prepared such that all can be amplified with one primer pair. After overnight
hybridization to immobilized genomic DNA, unbound probes are removed by stringent washing. Bound probes are then released and amplified
in a quantitative manner. By fluorescent labeling and capillary electrophoresis, it is possible to both discriminate and quantify each probe.
Changes in peak heights correspond to copy-number changes (i.e., deletions and duplications).
mutations inDMD lead to the lethal phenotype ofDMD,
whereasmutations that retain the reading frame generally
cause the less severe phenotype of Becker muscular dys-
trophy (BMD) (Monaco et al. 1988; Koenig et al. 1989).
An accurate molecular diagnosis is therefore essential
both to confirm the clinical diagnosis and to distinguish
the two allelic forms.
In approximately two-thirds of cases, the mutation is
a deletion or duplication of one or more of the exons,
clustered in two hotspot regions (Forrest et al. 1987;
Koenig et al. 1987; Darras et al. 1988; den Dunnen et
al. 1989; Gillard et al. 1989). In affected male patients,
deletion detection is relatively simple. Formultiplex PCR,
two nine-exon sets (the Chamberlain et al. [1988] and
Beggs et al. [1990] sets) have been designed around these
hotspots, which together detect 90%–95% of the dele-
tions in male patients. Alternative methods must be ap-
plied to determine the exact boundaries of the deletion,
as well as to detect duplications and carrier status in
female individuals. The size (2.4Mb) and complexity (79
exons) of DMD, however, make this a daunting task.
Quantitative Southern blotting has been the most com-
monly used technique (den Dunnen et al. 1989; Hu et
al. 1990; Yamagishi et al. 1996). By the comparison of
band intensities between test samples and control sam-
ples, it is possible to detect copy-number changes in the
individual exons. The preparation of high-quality blots
is technically demanding, and six to eight hybridizations
are required in order to scan all the exons. In addition,
duplication detection is difficult, especially in female
carriers and when the duplications are small (i.e., cov-
ering only one or two exons). Quantitative PCR is an-
other, more recently applied technique (Ioannou et al.
1992; Mansfield et al. 1993; Yau et al. 1996), in which
a multiplex PCR is performed that has a limited number
of cycles, ensuring that quantitative products are yielded.
Again, the technique is technically demanding, and the
incomplete coverage of the exons means that mutations
outside the hotspots will be missed. Not surprisingly,
therefore, mutation-analysis reports differ considerably
in the frequency of duplications detected, ranging be-
tween 0 and 6%, depending on the techniques applied
for analysis (Koenig et al. 1987; den Dunnen et al. 1989;
Hu et al. 1990; Mendell et al. 2001).
Here we describe a MAPH-based method that scans
all 79 DMD exons for deletions and duplications. We
have been able to detect and define a large series of new
mutations—in particular, duplications—with several not
detected by Southern blotting and/or quantitative PCR.
The simplicity of this technique should allow its easy
implementation in diagnostic laboratories, and its utility
means that it can be readily adapted for the screening of
duplications and deletions in any genetic disease.
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Figure 2 Example of trace patterns obtained from an unaffected male individual. The numbers refer to DMD exon numbers: “1.x” and
“2.x” (where x is the exon number) refer to BRCA1 and BRCA2, respectively, and “NF2” denotes a probe homologous to the first exon of
the NF2 gene. Asterisks (*) indicate control peaks, and unlabeled peaks indicate noise. Probes range in size from 151 bp (DMD exon 34) to
602 bp (DMD exon 2).
Methods
Probe Generation
All probes were based on individual exons. SomeDMD
probes were created using primers from the Chamberlain
et al. (1988) and Beggs et al. (1990) kits. The remainder
were based on sequences obtained from the LeidenMus-
cular Dystrophy Pages. To facilitate analysis, we pre-
pared control probes by using genomic sequence ob-
tained from GenBank. For each product, the presence
of duplicated and/or repetitive sequences was excluded
using the BLAST program. The sequences were checked
against the nr (nonredundant) and htgs (high-through-
put genomic sequences) databases. No probe showed an
intraspecies homology 190% for a stretch of 30 nt
(expected value 1e11).
Products were amplified from genomic DNA by PCR
and were cloned into the pGEM-T easy vector (Promega).
The correct insert was confirmed by sequencing through
use of the BigDye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems). This was performed
at the Leiden Genome Technology Center, where reac-
tions were analyzed on the ABI 3700 Sequencer (Applied
Biosystems).
Each probe was amplified from the vector by use of
the primers MAPH-F1 (GGCCGCGGGAATTCGATT)
and MAPH-R1 (GCCGCGAATTCACTAGTG). Prod-
ucts were purified with theQiagen PCR cleanup kit (Qia-
gen) and were then added to the appropriate probe mix-
ture, which had a final concentration of 100–500 pg/ml.
Probe sets A and B were prepared containing 40 and 39
DMD exons, respectively. Nine-probe control mixtures
were made specifically for use with each probe set.
MAPH
MAPH was performed using a protocol adapted from
the original MAPH protocol (Armour et al. 2000), as
follows (for detailed protocol, see the Leiden Muscular
Dystrophy Pages). At least 1 mg genomic DNA was de-
natured in 1 ml 1N NaOH and spotted on a small nylon
filter, followed by UV cross-linking. Up to 16 filters were
hybridized together in one tube; the filters were prehy-
bridized in 1 ml prehybridization solution (0.5 M so-
dium phosphate [pH 7.2], 1 mM EDTA, 7% SDS, and
100 ng/ml Herring Sperm DNA [Gibco BRL]) for ∼2 h
at 60C; this solution was replaced with 200 ml prehy-
bridization solution that contained 2 mg denatured Cot1
DNA (Gibco BRL) and was incubated at 60C for 30
min. Probe mixture (1 ml combined probes, 1 ml Cot1
DNA [1 mg/ml], 1 ml Herring Sperm DNA [10 mg/ml;
Gibco BRL], 1 ml blocking mixture [blocking primers
that each had a final concentration of 20 mM], and 3 ml
H2O) was denatured by the addition of 2 ml 1N NaOH
and incubated at 37C for 1 min. After cooling on ice,
3 ml 1M NaH2PO4 was added, and the mixture was
added to the tube that contained the filters. Hybridi-
zation was performed overnight at 60C. Washing was
performed the next day with five times in 25 ml salt-
sodium citrate (SSC) and 1% SDS, followed by five
washes in 25 ml 0.1# SSC and 0.1% SDS, all at 60C.
Each filter was transferred to a PCR tube, and a five-
cycle PCR amplification was performed under the fol-
lowing conditions: 94C for 5 min; five cycles of 94C
for 45 s, 57C for 1 min, and 68C for 1 min; and 68C
for 10 min.
Two and one-half microliters of this mixture was trans-
ferred to a second PCR, which was performed under the
Table 1
Samples Screened
SAMPLE (SEX) METHOD(S)a
MUTATION FOUNDb BY
Other
Methods MAPH
D1 (M) 1,3 Del 5-7 Del 5-7
D2 (F) Dup 52-55
D3 (M) 3 Del 50 Del 50
D4 (F) Dup 50-55
D5 (M) 1,3 nm Dup 50-55
D6 (M) 3 Del 8-44 Del 8-44
D7 (M) 1,3 nm nm
D8 (M) 1,3 Dup 43 Dup 43
D9 (F) Dup 58-63
D10 (M) 1,3 ?c Dup 58-63
D11 (M) 3 Del 49-52 Del 49-52
D12 (M) 3 Del 48-50 Del 48-50
D13 (F) Del 45
D14 (M) 3 Del 1m Del 1m
D15 (M) 3 nm Del 53
D16 (M) 1,3 nm nm
D17 (M) 3 Del (3)-(10) Del 4-12
D18 (M) 3 Del 14-60 Del 14-60
D19 (M) 1,3 Del 69 Del 64-67
D20 (F) 3 Del (45)-(50) Del 49-54
D21 (M) 3 Del 2-(33) Del 2-30
D22 (M) 3 nm nm
D23 (M) 3 Dup 12 Dup 12
D24 (F) Dup 2
D25 (M) 2,3 nm Dup 2
D26 (M) 1,3 nm nm
D27 (F) Dup 12-13
D28 (F) Dup 44
D29 (M) 3 Dup 2-9 Dup 2-9
D30 (F) nm
D31 (M) 3 Del 1-79 Del 1-79
D32 (F) 3 Dup 44-57 Dup 44-57
D33 (F) Dup 2-7
D34 (M) 1,3 Dup 2-7 Dup 2-7
D35 (M) 1,3 Dup 2-7 Dup 2-7
D36 (F) 3 Del 10-(?) Del 10-46
D37 (M) 3 Del 3-(?) Del 3-19
D38 (F) 3 Del (50) Del 48-50
D39 (M) nm
D40 (M) 1,3 Del 46-51 Del 46-51
D41 (M) 3 Del XJ10d Del 4-13
D42 (M) 2,3 Del 3-16 Del 3-16
D43 (M) 1,3 nm nm
D44 (F) 2,3 Dup 2e Dup 2
D45 (M) Dup 2
D46 (F) 3 nm nm
D47 (M) 1,3 nm nm
D48 (M) 1,3 nm nm
D49 (M) 3 Del 8-(16) Del 8-39
D50 (M) 1,3 nm nm
D51 (F) 2,3 nm nm
D52 (M) 1,2,3 Dup 51 Dup 51
D53 (M) 1,3 nm nm
D54 (M) 1,3 nm nm
D55 (M) 1,3 nm nm
D56 (M) 1,3 nm nm
D57 (M) Dup 6
D58 (M) 1,3 nm nm
D59 (M) 1,2,3 nm nm
D60 (M) 1,3 nm nm
D61 (M) 1,3 Del 2-7 Del 3-6
D62 (M) 1,2,3 Del 20-29 Del 20-29
D63 (F) Dup 2-(7) Dup 3-7
D64 (M) Dup 17 Dup 17
D65 (M) 1,2,3 nm nm
D66 (F) nm
D67 (M) 1,2,3 Del 19-43 Del 21-43
D68 (M) 1,2,3 Del 19-43 Del 21-43
(continued)
Table 1 (continued)
SAMPLE (SEX) METHOD(S)a
MUTATION FOUNDb BY
Other
Methods MAPH
D69 (M) 1,3 nm nm
D70 (F) Dup 3-7 Dup 3-7
D71 (M) Dup 3 Dup 3
D72 (F) Dup 3
D73 (M) 1,2,3 nm nm
D74 (M) Dup 51-55 Dup 51-55
D75 (F) 2,3 Dup 51-55 Dup 51-55
G1 (M) 1,4 nm Del 21
G2 (M) 1,4 nm Dup 10-11
G3 (M) 1,4 nm Dup 18-23
G4 (M) 1,4 nm nm
G5 (M) 1,4 nm Del 48
G6 (M) 1,4 nm Dup 6-7
G7 (M) 1,4 nm Del 66
G8 (M) 1,4 nm nm
G9 (M) 1,4 nm nm
G10 (F) 1,4 nm Del 48-50
G11 (M) 1,4 nm nm
H1 (M) 1 nm nm
H2 (M) 1 nm nm
H3 (M) 1 nm nm
H4 (F) 1 nm nm
H5 (M) 1 nm Del 45-50
H6 (M) 1 nm Dup 44
H7 (M) 1 nm nm
H8 (M) 1 nm nm
H9 (M) 1 nm nm
H10 (M) 1 nm Dup 3-4
L1 (M) 1,4 nm Dup 8-13
L2 (M) 1,4 nm Del 18
L3 (M) 1,4 nm nm
L4 (M) 1,4 nm nm
L5 (M) 1,4 nm Dup 5-6
L6 (M) 1,4 nm Dup 54
L7 (M) 1,4 nm Dup 8-9
L8 (M) 1,4 nm nm
L9 (M) 1,4 nm Dup 45-52
L10 (M) 1,4 nm Dup 2
L11 (M) 1,4 nm Dup 8-13
L12 (M) 1,4 nm Dup 53-55
L13 (M) 1,4 nm Dup 61-64
L14 (M) 1,4 nm nm
L15 (M) 1,4 nm Dup 51-57
L16 (M) 1,4 nm Dup 8-9
L17 (M) 1,4 nm Dup 2
L18 (M) 1,4 nm Dup 3-30
L19 (M) 1,4 nm Dup 20
L20 (M) 1,4 nm Dup 14-21
L21 (M) 1,4 nm nm
L22 (M) 1,4 nm Dup 2
L23 (M) 1,4 nm Dup 8-9
L24 (M) 1,4 nm Dup 42-43
L25 (M) 1,4 nm Dup 6-7
L26 (M) 1,4 nm Del 56
L27 (M) 1,4 nm nm
M1 (M) 1,4 nm Dup 18-32
M2 (M) 1,4 nm Dup 20-27
a 1 p PCR by use of the Chamberlain et al. (1988) and Beggs et al. (1990)
sets; 2 p quantitative Southern blotting; 3p quantitative multiplex PCR; 4p
point-mutation detection.
b Del p deletion; Dup p duplication; nm p no mutation found. Numbers
denote exons; those in parentheses indicate an uncertain breakpoint.
c Duplication of 30–50 kb around exon 60 detected using pulsed-field gel
electrophoresis.
d Probe located in intron 7.
e Detectable by quantitative PCR, not evident with quantitative Southern
blotting.
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Figure 3 Patterns obtained from analysis of patients by use of probe set A. A, Male patient’s duplicated exon 2, male patient’s duplicated
exons 14–21, and male control individual. B, Female carrier’s duplicated exons 52–54 and female control individual.
same conditions as the first reaction except that one of
the primers was fluorescently labeled and the reactionwas
for 23 cycles. Two microliters of this product was added
to 10 ml (Hi Di) Formamide (Applied Biosystems) and
0.15 ml ROX-500 size standard (Applied Biosystems) in
a 96-well plate. This was heated at 95C for 5 min,
followed by immediate cooling on ice. The samples were
analyzed on an ABI 3700 capillary sequencer (Applied
Biosystems).
Data Analysis
Data were analyzed using the programs Gene Scan
(Applied Biosystems) and Excel (Microsoft). Peaks
were considered unreliable if they were outside pre-
defined thresholds (upper and lower limits of 12,000
and 150 units, respectively).
Male samples were initially visually assessed, to detect
any deletions. Presence of a peak that corresponds to a
Y chromosome–specific probe confirmed the sex of the
sample. Absence of one or more DMD peaks was taken
to be a deletion, and no calculations were performed.
Samples were analyzed using a combination ofmethods
described for analysis of MAPH (Armour et al. 2000;
Sismani et al. 2001) and array-based comparative ge-
nomic hybridization (Hodgson et al. 2001) experiments.
In the original MAPH publication (Armour et al. 2000),
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Figure 4 Analysis of different patient samples. A, Male patient
L1’s duplicated exons 8–13, with SD 0.05. B, Female carrier D36’s
deleted exons 10–46, with SD 0.05 C, Female carrier D70’s duplicated
exons 3–7, with SD 0.06.
each peak was compared with the two nearest peaks, for
normalization. Since each DMD exon could potentially
be altered in copy number, we also added probes from
exons of autosomal genes unrelated to DMD. For each
dystrophin exon, the peak height was divided by the sum
of the peak heights of the two nearest unlinked probes,
to give a ratio. Within one hybridization, the median of
the ratio for each exon was calculated and was used as
a reference value against which all exons were compared.
Each exon was divided by this number, thereby normal-
izing all unaffected exons to 1.0. For each sample, initial
estimates for deletions or duplications were performed
visually, by setting arbitrary thresholds on the basis of
expected ratios (Hodgson et al. 2001). Wild-type exons
were expected to fall in the ranges of for male1.0 0.5
patients and for female carriers. The median1.0 0.25
and SD of the exons that fell within this range were cal-
culated, and each exon was divided by the median to
correct for variations between samples. Any exon that
was outside 3 SDs of the “normal” exons was assumed
to be altered in copy number. Samples that showed an
SD 115% over the unaffected exons or that appeared
to show noncontiguous deletions or duplications were
deemed to be unreliable.
Results
Probes were initially tested by hybridization to control
DNA from 24 healthy individuals, as well as to DNA
from a patient with a deletion encompassing the entire
DMD gene. From the control samples, all the probes
could be recovered (fig. 2), whereas only control probes
from outside DMD were recovered from the patient
sample (data not shown). Thus, none of the probes
hybridize to other regions in the genome, which would
lead to false-positive signals.
A total of 125 samples were screened in a semiblind
manner (table 1 and figs. 3 and 4). These were a mixture
of fully and partially characterized cases, as well as sam-
ples from cases in which no mutation had been found.
In several cases, the DNA was from a potential carrier
in whom the mutation sought was already known. With
a threshold of 3 SDs and the assumption that the unaf-
fected ratios are normally distributed, a false-positive re-
sult should only occur ∼0.3% of the time, which is the
equivalent of one exon per four DMD genes tested. This
is approximately the ratio of false-positive results seen
among samples that were not excluded for other reasons
(e.g., peak height being outside the boundaries or SD
being 115%). Therefore, all samples that showed a sin-
gle-exon rearrangement were tested at least twice. Fol-
lowing these criteria, we found no sample that showed
evidence of more than one mutational event.
False-negative results are more difficult to assess. An
estimate can be made by looking at patient samples in
which more than two exons are deleted or duplicated.
A result would be considered to be false negative when
one or more exons within a mutated series was found
to be normal. In no patient sample was this seen. Al-
though this does not exclude the possibility that false-
negative calls will occur, it does suggest that they will
happen very rarely.
The exon 75 probe was the probe that showed the
highest variation among the 79DMD probes used. This
appeared to be due to slight variations in PCR/washing
conditions, rather than variations in a polymorphic se-
quence, since no sample consistently showed a dupli-
cation of exon 75. For any hybridization in which exon
75 showed such variation, the results for that exon were
ignored, and the exon was retested in a subsequent ex-
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Figure 5 Independent mutations detected during the present study. Vertical bars represent the 18 exons tested using the Chamberlain et
al. (1988) and Beggs et al. (1990) kits. A, Mutations detected in samples in which point mutations and deletions had been excluded, mainly
by multiplex PCR. B, All other mutations detected.
periment. In no cases could an exon 75 duplication be
confirmed.
Initially, some probes could not be recovered. Close
examination of the sequences revealed that all had a
relatively low GC content (!40%). In some cases—for
example, exon 2—it was not possible to raise this per-
centage, since the entire region was extremely AT rich.
To solve this problem, we made the probes longer. In
this manner, we were able to use a 602-bp exon 2 probe
with a GC content as low as 30%.
Discussion
Of the 24 mutations previously characterized in our lab-
oratory, all were detected using the MAPH technique
(table 1). In one case, the breakpoints did not match
exactly. This was in a male patient (D61) that, with
MAPH, was seen as having a deletion of exons 3–6 but
had previously been diagnosed as having a deletion of
exons 3–7. Southern blot analysis showed a junction
fragment for exon 7, suggesting that the breakpoint may
be within the exon. In a hybridization-based technique,
a breakpoint may be misdiagnosed if the deletion occurs
within the sequence to which it is bound by the probe
and if there is enough of the exon remaining for the
probe to hybridize; this is likely to occur rarely however,
since it has been calculated that, in ∼99% of cases of
DMD and/or BMD, the breakpoints are outside the cod-
ing exon (den Dunnen et al. 1989). By contrast, PCR
from genomic DNA may lead to false-negative results if
there is a polymorphism within the priming site (Abbs
et al. 1991).
Of the 72 male samples in which no mutation had
previously been found, 37 (51%) had mutations that
were detectable by use of MAPH (table 1). When only
those samples that had been checked for deletions and
point mutations were included, the frequency was 74%
(29/39). These were composed of five deletions (all of
one exon) and, strikingly, but not unexpectedly, 24 du-
plications. To present an unbiased view of duplication
distribution, we have depicted those mutations detected
in samples that were also screened for point mutations
and deletions (fig. 5A) separately from an overview of
all the mutations detected (fig. 5B).
Samples LA1–LA27 (table 1) were from a point-mu-
tation screening by use of the DOVAM-S (detection of
virtually all mutations–SSCP) technique (Mendell et al.
2001). A total of 141 samples were tested, and 108 point
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mutations were found. We analyzed 27 of the remaining
33 samples, finding two deletions and 20 duplications.
Samples M1 and M2 (table 1) remained from a study,
using denaturing high-performance liquid chromatog-
raphy, that screened eight patients with DMD for point
mutations (Bennett et al. 2001) but found no obvious
pathological mutations in two of these samples. By use
of MAPH, both samples showed a duplication, thereby
completing the mutation study.
A total of 23 female potential or proven carriers were
tested. Of the 15 samples in which no mutation had
previously been found, two deletions and eight dupli-
cations were found. Analysis of potential carriers was
facilitated when it was known what mutation to expect.
Newly found mutations could often be confirmed us-
ing other methods. Small duplications, such as that in
sample D52 (with an exon 51 duplication), could be
confirmed by retrospective examination of Southern
blots that had been previously prepared and analyzed
in our laboratory. The DNA in sample D45 showed an
exon 2 duplication by use of MAPH, as did DNA from
the mother (sample D44). The result from sample D44
was confirmed by quantitative PCR, yet was not evident
on a Southern blot.
The exon 2 (samples D25 and D120.7) and exons
58–63 (samples D10 and DL33.2) duplications, which
have been described elsewhere (den Dunnen et al. 1989),
are interesting cases. Pulsed-field gel electrophoresis anal-
ysis indicated that there were rearrangements of ∼150
kb, at the 5′ end of the gene, and 30–50 kb, around exon
60. Despite a focused analysis of both regions, no du-
plications could be detected using Southern blotting.
Duplication of exon 2 alone is extremely difficult to
detect by Southern blotting, since the band is very weak.
This may be due to the very low GC content (∼30%) of
exon 2 and its surrounding region, leading, under strin-
gent conditions, to weak hybridization. Given the ex-
tremely large size (190 and 170 kb) of the introns flanking
exon 2, it is not surprising that a deletion or duplication
of exon 2 by itself is a mutation that has been found
more than once. In fact, it was the single most common
duplication found, occurring five times. Interestingly,
however, no deletion of exon 2 alone has so far been
reported (Leiden Muscular Dystrophy Pages).
Our results show that, even when the DMD gene is
screened for deletions, duplications, and point muta-
tions (DOVAM-S or denaturing gradient gel electro-
phoresis), a small number of samples remain in which
no disease-causing mutation can be detected. There are
several possible explanations why no mutation was
found in these samples. When RNA has not yet been
analyzed in a patient, mutations that affect splicing are
the most plausible candidates. Indeed, RNA-based tech-
niques, such as the protein-truncation test, detect mu-
tations that would be missed using DNA-based tech-
niques (Roest et al. 1996; Whittock et al. 1997). It is
also possible that the disease was misdiagnosed and that
the mutation lies in a gene responsible for other mus-
cular disorders. Germline mosaicism has been reported
elsewhere (Bakker et al. 1987; Wood and McGillivray
1988) and would not necessarily be detectable by use
of the methods described herein. Another, less likely
reason is mutations in a gene that is involved in the
regulation of dystrophin expression.
Although mutation detection obviously is critical for
diagnosis, it may also be important for future therapeutic
purposes. Recent reports have showed the potential use
of read-through protein synthesis (Gentamycin) (Barton-
Davis et al. 1999) and exon skipping (with antisense
oligoribonucleotides) (van Deutekom et al. 2001) in the
restoration of the reading frame of the dystrophin tran-
script. In particular, single-exon duplications, as detected
in 12 cases in this study, would make an ideal target for
exon skipping. The presence of two targets not only
would double the efficiency but also should produce a
normal transcript, leading to a wild-type protein.
The MAPH approach’s primary advantages over
Southern blotting and quantitative PCR are the relative
simplicity, speed, and completeness of coverage of all 79
exons. Although 90%–95% of the deletions can be de-
tected using multiplex PCR, the breakpoints are often
not determined, and rare mutations outside the hotspots
will be missed. In previously published reports onMAPH
(Armour et al. 2000; Sismani et al. 2001), recovered
probes were radioactively labeled and were separated on
a polyacrylamide gel. For speed and convenience, we
chose to use a combination of fluorescent labeling and
capillary electrophoresis. Capillary electrophoresis is be-
coming more widely used in mutation detection, since it
provides greater sensitivity and has high-throughput
capabilities (Bosserhoff et al. 2000). We used the ABI
3700 (Applied Biosystems), which allows the simul-
taneous analysis of 96 samples. One run of 96 samples
takes ∼4 h, with the data analyzed by software pro-
vided with the machine.
There are several ways in which the current system
can be further enhanced. In the present study, only two
(blue [FAM sample] and red [ROX size standard]) of
the four available colors were used. By use of up to
three sets of primers, each labeled with a different fluo-
rophore, it should be possible to expand the potential
number of probes by threefold. Hybridizing the PCR
products to a microarray composed of each individual
probe could further increase the number of probes
tested, with the additional advantage that they would
no longer need to be differentiated in length.
In contrast to many other methods, this technique
should be easy to implement in a standard diagnostic
laboratory, since no new technology needs to be in-
troduced. The critical techniques are hybridization and
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PCR, and the products can be analyzed on any ap-
paratus that is used for sequence analysis. Further-
more, it can easily be applied to any disease gene of
interest, and the resolution provided and the potential
of array implementation may even allow future ge-
nomewide screening.
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